Alkermes plc. (ALKS) stock
ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30213% above fair value
$47.89+1.42 (+3.06%)
Close on Nov 11, 2026Market cap $8.03BP/E 126.0Yield –
Alkermes r&d expenses
Research and development expenses are spending on new products and technology.
Alkermes's R&D Expenses for the twelve months ending Jun 30, 2026 was $391.04M, up 46.3% year over year. For fiscal 2025 it was $323.96M, up 32.1% from the year before. Over ten years it grew -0.6% a year on average. The highest annual figure on record is $512.83M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $323.96M | +32.1% |
| FY2024 | Dec 31, 2024 | $245.33M | -9.4% |
| FY2023 | Dec 31, 2023 | $270.81M | -0.7% |
| FY2022 | Dec 31, 2022 | $272.70M | -6.3% |
| FY2021 | Dec 31, 2021 | $290.92M | -26.3% |
| FY2020 | Dec 31, 2020 | $394.59M | -23.1% |
| FY2019 | Dec 31, 2019 | $512.83M | +20.6% |
| FY2018 | Dec 31, 2018 | $425.41M | +3.0% |
| FY2017 | Dec 31, 2017 | $412.89M | +6.6% |
| FY2016 | Dec 31, 2016 | $387.15M | +12.4% |
| FY2015 | Dec 31, 2015 | $344.40M | +146.0% |
| FY2013 | Mar 31, 2013 | $140.01M | -1.3% |
| FY2012 | Mar 31, 2012 | $141.89M | +45.9% |
| FY2011 | Mar 31, 2011 | $97.24M | +2.0% |
| FY2010 | Mar 31, 2010 | $95.36M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $112.92M | +45.9% |
| Q1 FY2026 | Mar 31, 2026 | $103.35M | +43.9% |
| Q4 FY2025 | Dec 31, 2025 | $93.04M | +59.9% |
| Q3 FY2025 | Sep 30, 2025 | $81.74M | +36.5% |
| Q2 FY2025 | Jun 30, 2025 | $77.37M | +29.7% |
| Q1 FY2025 | Mar 31, 2025 | $71.82M | +6.2% |
| Q4 FY2024 | Dec 31, 2024 | $58.17M | -21.3% |
| Q3 FY2024 | Sep 30, 2024 | $59.89M | -7.7% |
| Q2 FY2024 | Jun 30, 2024 | $59.65M | -12.6% |
| Q1 FY2024 | Mar 31, 2024 | $67.61M | +6.0% |
| Q4 FY2023 | Dec 31, 2023 | $73.93M | -29.3% |
| Q3 FY2023 | Sep 30, 2023 | $64.88M | -35.4% |
| Q2 FY2023 | Jun 30, 2023 | $68.23M | -26.5% |
| Q1 FY2023 | Mar 31, 2023 | $63.77M | -33.5% |
| Q4 FY2022 | Dec 31, 2022 | $104.59M | +6.3% |
| Q3 FY2022 | Sep 30, 2022 | $100.43M | -15.2% |
| Q2 FY2022 | Jun 30, 2022 | $92.87M | -4.7% |
| Q1 FY2022 | Mar 31, 2022 | $95.95M | +4.0% |
| Q4 FY2021 | Dec 31, 2021 | $98.37M | -12.2% |
| Q3 FY2021 | Sep 30, 2021 | $118.41M | +24.7% |
| Q2 FY2021 | Jun 30, 2021 | $97.47M | +3.5% |
| Q1 FY2021 | Mar 31, 2021 | $92.27M | -1.1% |
| Q4 FY2020 | Dec 31, 2020 | $112.11M | -43.4% |
| Q3 FY2020 | Sep 30, 2020 | $94.98M | -11.8% |
| Q2 FY2020 | Jun 30, 2020 | $94.22M | -9.8% |
| Q1 FY2020 | Mar 31, 2020 | $93.28M | -9.1% |
| Q4 FY2019 | Dec 31, 2019 | $198.16M | +81.8% |
| Q3 FY2019 | Sep 30, 2019 | $107.67M | +6.3% |
| Q2 FY2019 | Jun 30, 2019 | $104.44M | -2.2% |
| Q1 FY2019 | Mar 31, 2019 | $102.57M | -5.3% |
| Q4 FY2018 | Dec 31, 2018 | $108.97M | +4.3% |
| Q3 FY2018 | Sep 30, 2018 | $101.27M | -3.0% |
| Q2 FY2018 | Jun 30, 2018 | $106.82M | +7.7% |
| Q1 FY2018 | Mar 31, 2018 | $108.35M | +3.3% |
| Q4 FY2017 | Dec 31, 2017 | $104.49M | +16.6% |
| Q3 FY2017 | Sep 30, 2017 | $104.41M | +5.0% |
| Q2 FY2017 | Jun 30, 2017 | $99.15M | – |
| Q1 FY2017 | Mar 31, 2017 | $104.84M | – |
| Q4 FY2016 | Dec 31, 2016 | $89.63M | – |
| Q3 FY2016 | Sep 30, 2016 | $99.44M | – |
See a number that looks wrong?